HC Wainwright Issues Pessimistic Forecast for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price

Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price cut by HC Wainwright from $4.00 to $3.50 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com upgraded Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP stock opened at $0.59 on Thursday. The firm has a market capitalization of $150.02 million, a price-to-earnings ratio of -2.67 and a beta of 2.26. The company has a current ratio of 3.85, a quick ratio of 3.09 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $0.88 and its 200-day moving average price is $1.03. Adaptimmune Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics in the third quarter valued at $33,000. Vontobel Holding Ltd. boosted its position in shares of Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics during the 3rd quarter worth approximately $95,000. Boulder Hill Capital Management LP bought a new stake in shares of Adaptimmune Therapeutics in the 1st quarter valued at $143,000. Finally, Jane Street Group LLC increased its stake in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.